Jazz Pharmaceuticals plcJAZZ
What Jazz Pharmaceuticals plc does.
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
• Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution , a product approved by FDA in July 2020, and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of IH in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®. Xywav is also approved in Canada for the treatment of cataplexy in patients with narcolepsy.
• Epidiolex® (cannabidiol) oral solution , a product approved by FDA and launched in the U.S. in 2018 by GW and currently indicated for the treatment of seizures associated with LGS, DS, or TSC in patients one year of age or older; in the EU and Great Britain (where it is marketed as Epidyolex®) and other markets, it is approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Net income | $238.6M | -$329.7M | -$224.1M | $414.8M | $560.1M | -$356.1M |
| Free cash flow | $884.6M | $750.9M | $1.2B | $1.1B | $1.4B | $1.3B |
More on JAZZ.
- Jazz Pharmaceuticals plc summary
- Jazz Pharmaceuticals plc financial statements
- Jazz Pharmaceuticals plc key metrics
- Jazz Pharmaceuticals plc health scores and style box
- Jazz Pharmaceuticals plc earnings
- Jazz Pharmaceuticals plc dividends
- Jazz Pharmaceuticals plc valuation
- Jazz Pharmaceuticals plc ownership and insiders
- Jazz Pharmaceuticals plc peers
Figures from Jazz Pharmaceuticals plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.